BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol 2020; 26(38): 5896-5910 [PMID: 33132643 DOI: 10.3748/wjg.v26.i38.5896]
URL: https://www.wjgnet.com/1007-9327/full/v26/i38/5896.htm
Number Citing Articles
1
Spyridon Zouridis, Ye H. Oo, Wing-Kin Syn. Role of Sirolimus and Rituximab in the Treatment of Autoimmune HepatitisACG Case Reports Journal 2024; 11(7): e01414 doi: 10.14309/crj.0000000000001414
2
KASL clinical practice guidelines for management of autoimmune hepatitis 2022Clinical and Molecular Hepatology 2023; 29(3): 542 doi: 10.3350/cmh.2023.0087
3
Linda Skibsted Kornerup, Lisbet Grønbæk, Mikkel Breinholt Kjær, Henning Grønbæk. Comprehensive Guide to Hepatitis Advances2023; : 429 doi: 10.1016/B978-0-323-98368-6.00026-4
4
Yang Zhang, Dehe Zhang, Ling Chen, Jing Zhou, Binbin Ren, Haijun Chen. The progress of autoimmune hepatitis research and future challengesOpen Medicine 2023; 18(1) doi: 10.1515/med-2023-0823
5
Ja Kyung Kim. Treatment of Autoimmune HepatitisThe Korean Journal of Gastroenterology 2023; 81(2): 72 doi: 10.4166/kjg.2023.011